{"id":"lenvatinib-losartan","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Hyperkalemia (from losartan)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenvatinib is a multi-targeted kinase inhibitor that suppresses tumor vasculature and cancer cell proliferation by inhibiting FGFR, VEGFR, and RET signaling. Losartan, an angiotensin II receptor antagonist, is co-administered to mitigate hypertension and other cardiovascular adverse effects commonly associated with lenvatinib monotherapy. This combination approach aims to improve tolerability while maintaining anti-tumor efficacy.","oneSentence":"Lenvatinib inhibits multiple receptor tyrosine kinases (FGFR, VEGFR, RET) to suppress tumor angiogenesis and growth, while losartan blocks angiotensin II receptors to manage hypertension and potentially reduce treatment-related cardiovascular toxicity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:33:54.670Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Radioactive iodine-refractory differentiated thyroid cancer (lenvatinib component)"},{"name":"Hepatocellular carcinoma (lenvatinib component)"},{"name":"Hypertension management and cardiotoxicity mitigation in lenvatinib-treated patients"}]},"trialDetails":[{"nctId":"NCT07160361","phase":"PHASE4","title":"Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Xi'an Jiaotong University","startDate":"2025-10-01","conditions":"Carcinoma, Hepatocellular","enrollment":56},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lenvatinib + losartan","genericName":"Lenvatinib + losartan","companyName":"Second Affiliated Hospital of Xi'an Jiaotong University","companyId":"second-affiliated-hospital-of-xi-an-jiaotong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenvatinib inhibits multiple receptor tyrosine kinases (FGFR, VEGFR, RET) to suppress tumor angiogenesis and growth, while losartan blocks angiotensin II receptors to manage hypertension and potentially reduce treatment-related cardiovascular toxicity. Used for Radioactive iodine-refractory differentiated thyroid cancer (lenvatinib component), Hepatocellular carcinoma (lenvatinib component), Hypertension management and cardiotoxicity mitigation in lenvatinib-treated patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}